I clinical trial will be composed of approximately 40 volunteers and will determine the safety and immunogenicity of the Company's vaccine. The vaccine consists of whole killed H. pylori cells in combination with a mucosal adjuvant. We are looking towards this trial to provide evidence that our vaccine will be useful as a prophylactic and potential therapeutic treatment of H. pylori disorders in humans. H. pylori is a common bacterial pathogen of humans worldwide. H. pylori is the major cause of chronic active gastritis and peptic ulcer disease and a risk factor for gastric cancer.
Infection also increases the risk of other diseases, including persistent diarrhea.
Antex is a biopharmaceutical company dedicated to the production of clinical technologies and therapeutic products to assist the world community in identifying, preventing and treating infectious diseases and related disorders. The company had two other vaccines in clinical development. Statements contained herein that are not historical facts may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.